Modality
Gene Editing
MOA
CDK4/6i
Target
APOC3
Pathway
RAS/MAPK
Bladder Ca
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
Aug 2019
→ May 2030
Phase 1Current
NCT03360384
1,004 pts·Bladder Ca
2019-08→2030-05·Completed
1,004 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-094.1y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2030-05-09 · 4.1y away
Bladder Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03360384 | Phase 1/2 | Bladder Ca | Completed | 1004 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-1969 | Roche | Approved | BET | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |